Navigation Links
FDA Panel Mulls Newer Antipsychotics for Kids

Seroquel, Zyprexa have been linked to certain health risks, experts note,,

WEDNESDAY, June 10 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel is expected to vote Wednesday on whether several powerful but controversial antipsychotic drugs be approved for use by children.

The drugs in question include new-generation "atypical" antipsychotics such as Geodon, Seroquel, and Zyprexa, currently approved for adult use. The medications are also being prescribed "off-label" by many doctors to treat schizophrenia and bipolar disorder in children ages 10 to 17, despite possible serious side effects, including diabetes and heart woes.

There is a pressing need for effective antipsychotics for children, one expert noted.

"Schizophrenia and bipolar disorder are very real illnesses, which collectively affect between 1 percent and 3 percent of all young people," noted Dr. David Fassler, a clinical professor of psychiatry at the University of Vermont College of Medicine, who testified before the panel Tuesday. "Without treatment, children have problems at school, at home, and with their friends. They're also at increased risk of accidents, hospitalization, and death at an early age from multiple causes, including suicide."

Fortunately, treatment is available to help children and adolescents who suffer from schizophrenia and bipolar disorder, including the medications being considered by the FDA panel, Fassler added.

Drug maker AstraZeneca is asking the FDA to let it market Seroquel to adolescents with schizophrenia and bipolar mania, also called manic depressive disorder. Pharmaceutical giant Lilly is asking for the same permission for its drug, Zyprexa. In addition, drug maker Pfizer wants approval to market a third atypical antipsychotic, Geodon, used to treat bipolar disorder, to patients 10 to 17.

And yet safety concerns plague many of these drugs. In 2004, the FDA ordered AstraZeneca to add a special "black box" warning to Seroquel's packaging, outlining increased risks of hyperglycemia, high blood pressure and diabetes associated with use of the drug. Also, older patients with dementia-related psychosis treated with Seroquel are at an increased risk of death, according to the FDA.

And in a unanimous vote in early April, an FDA advisory panel determined that Seroquel should not be approved as first-line therapy for adult depression, because of continued questions about its safety profile -- most notably, a link to higher risk for sudden cardiac death. However, the drug was approved for use in patients for whom other antidepressants didn't work.

The family of atypical antipsychotics has other well-documented potential side effects, including weight gain and high blood sugar, which can increase the risk of diabetes, as well as rapid heart beat, difficulty sleeping and trouble concentrating.

Prior studies have also found that these newer drugs are no more effective than older medications. Their main advantage is that they do not cause the tremors and muscle spasms associated with older agents.

Cost is an issue, as well: According to the Associated Press, these newer drugs are patent-protected and costs range between $300 to $500 per month, compared with about $100 per month for older antipsychotics.

There's also concern about the rapid increase in the use of these medications in pediatric populations in the absence of adequate research on long-term safety and efficacy, Fassler said.

"None of these medications should be used without careful considerations of the risks and benefits," Fassler said. "Children and adolescents taking these medications should be monitored closely for evidence of significant side effects or adverse reactions. Nonetheless, when used appropriately, these medications can be a helpful and effective component of treatment for children and adolescents with schizophrenia or bipolar disorder," he added.

Ronald T. Brown, dean and professor of public health at Temple University Health Sciences Center, also testified before the panel on Tuesday. He told the experts that there is still too little known about the efficacy and side effects of these medications in children to make them a standard of care.

"Serious questions have not been answered regarding the long-term effectiveness and, more importantly, safety of atypical antipsychotics in treating childhood disorders," Brown told the panel. "Continued, strong development of the research and knowledge base related to serious emotional disturbance and its treatment during childhood should be of the highest priority, and finally, physicians may continue prescribing Geodon, Seroquel, and Zyprexa off-label to children, as we continue to grow this knowledge base."

In any case, drugs should never be viewed as the only therapeutic option open to young patients, according to Fassler.

"Medication, including the atypical antipsychotics, can be helpful to control some of the signs and symptoms associated with these disorders, but medication alone is rarely an adequate or sufficient intervention. It should only be used as part of a comprehensive treatment plan, individualized to the needs of the child and family," Fassler said.

Although the FDA isn't required to follow advisory committee recommendations, it usually does.

More information

For more information on atypical antipsychotics, visit the U.S. Food and Drug Administration .

SOURCES: David Fassler, M.D., clinical professor of psychiatry, University of Vermont College of Medicine, Burlington; Ronald T. Brown, Ph.D., dean and professor of public health, Temple University Health Sciences Center, Philadelphia; June 10, 2009, Associated Press

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
Related Image:
FDA Panel Mulls Newer Antipsychotics for Kids 
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... to be a safe and convenient way to dispense prescription medications at home, ... safe and effective way to monitor and dispense prescription medications. In doing so, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... $15.8  Million to expand its laboratories and global ... The expansion will provide additional office space and ... of the pharmaceutical and biotechnology markets. ... up to 40,000 square feet of expanded development ...
(Date:11/25/2015)... -- ARKRAY USA , Inc., a leader ... the accuracy of its blood glucose meter systems. Last ... and Cardiovascular Disease in Los Angeles ... 01 meter and the Assure ® Prism ... accurately measure glucose levels in blood is essential for ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
Breaking Medicine Technology: